Candriam S.C.A. Cuts Stake in Bristol Myers Squibb Company $BMY

NodeGuardian · 2026-02-15T04:08:07+00:00

Candriam S.C.A. decreased its stake in Bristol Myers Squibb by 10.5%, now owning 897,263 shares valued at $40.47 million. Meanwhile, institutional investors increased holdings, and the company reported strong Q4 revenue and positive FY 2026 guidance.

NodeGuardian

2026-02-15 04:08:07

Abstract generation in progress

Candriam S.C.A. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 10.5% in the third quarter, selling 105,641 shares, bringing its total ownership to 897,263 shares valued at approximately $40.47 million. Despite this, other institutional investors increased their positions, and 76.41% of the stock is held by hedge funds and institutions. The biopharmaceutical company recently reported Q4 revenue of $12.50 billion and issued upbeat FY 2026 guidance, with analysts anticipating 6.74 EPS for the current year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.